385 related articles for article (PubMed ID: 15466872)
21. Analysis of the N-terminal positively charged residues of the simian immunodeficiency virus Vif reveals a critical amino acid required for the antagonism of rhesus APOBEC3D, G, and H.
Schmitt K; Katuwal M; Wang Y; Li C; Stephens EB
Virology; 2014 Jan; 449():140-9. PubMed ID: 24418547
[TBL] [Abstract][Full Text] [Related]
22. New insights into the role of Vif in HIV-1 replication.
Schröfelbauer B; Yu Q; Landau NR
AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
[TBL] [Abstract][Full Text] [Related]
23. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
Zheng YH; Irwin D; Kurosu T; Tokunaga K; Sata T; Peterlin BM
J Virol; 2004 Jun; 78(11):6073-6. PubMed ID: 15141007
[TBL] [Abstract][Full Text] [Related]
24. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
25. HIV-2 Vif and foamy virus Bet antagonize APOBEC3B by different mechanisms.
Zhang Z; Perković M; Gu Q; Balakrishnan K; Sangwiman A; Häussinger D; Lindemann D; Münk C
Virology; 2021 Feb; 554():17-27. PubMed ID: 33333348
[TBL] [Abstract][Full Text] [Related]
26. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
Chaipan C; Smith JL; Hu WS; Pathak VK
J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
[TBL] [Abstract][Full Text] [Related]
27. Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.
Britan-Rosich E; Nowarski R; Kotler M
J Mol Biol; 2011 Jul; 410(5):1065-76. PubMed ID: 21763507
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K; de Noronha C; Yonemoto W; Greene WC
Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
[TBL] [Abstract][Full Text] [Related]
29. GANP interacts with APOBEC3G and facilitates its encapsidation into the virions to reduce HIV-1 infectivity.
Maeda K; Almofty SA; Singh SK; Eid MMA; Shimoda M; Ikeda T; Koito A; Pham P; Goodman MF; Sakaguchi N
J Immunol; 2013 Dec; 191(12):6030-6039. PubMed ID: 24198285
[TBL] [Abstract][Full Text] [Related]
30. A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection.
Yoshikawa R; Izumi T; Yamada E; Nakano Y; Misawa N; Ren F; Carpenter MA; Ikeda T; Münk C; Harris RS; Miyazawa T; Koyanagi Y; Sato K
J Virol; 2016 Jan; 90(1):474-85. PubMed ID: 26491161
[TBL] [Abstract][Full Text] [Related]
31. Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells.
Takeuchi H; Buckler-White A; Goila-Gaur R; Miyagi E; Khan MA; Opi S; Kao S; Sokolskaja E; Pertel T; Luban J; Strebel K
J Virol; 2007 Aug; 81(15):8080-90. PubMed ID: 17522232
[TBL] [Abstract][Full Text] [Related]
32. Cytidine deamination of retroviral DNA by diverse APOBEC proteins.
Bishop KN; Holmes RK; Sheehy AM; Davidson NO; Cho SJ; Malim MH
Curr Biol; 2004 Aug; 14(15):1392-6. PubMed ID: 15296758
[TBL] [Abstract][Full Text] [Related]
33. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
Albin JS; Brown WL; Harris RS
Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
[TBL] [Abstract][Full Text] [Related]
34. Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.
Zhang W; Huang M; Wang T; Tan L; Tian C; Yu X; Kong W; Yu XF
Cell Microbiol; 2008 Aug; 10(8):1662-75. PubMed ID: 18419775
[TBL] [Abstract][Full Text] [Related]
35. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
36. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
37. Insights into the dual activity of SIVmac239 Vif against human and African green monkey APOBEC3G.
Gaur R; Strebel K
PLoS One; 2012; 7(11):e48850. PubMed ID: 23189135
[TBL] [Abstract][Full Text] [Related]
38. Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F.
Nagao T; Yamashita T; Miyake A; Uchiyama T; Nomaguchi M; Adachi A
J Med Invest; 2010 Feb; 57(1-2):89-94. PubMed ID: 20299747
[TBL] [Abstract][Full Text] [Related]
39. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.
Shirakawa K; Takaori-Kondo A; Kobayashi M; Tomonaga M; Izumi T; Fukunaga K; Sasada A; Abudu A; Miyauchi Y; Akari H; Iwai K; Uchiyama T
Virology; 2006 Jan; 344(2):263-6. PubMed ID: 16303161
[TBL] [Abstract][Full Text] [Related]
40. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.
Alce TM; Popik W
J Biol Chem; 2004 Aug; 279(33):34083-6. PubMed ID: 15215254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
